LLY

LLY

15 Companies Reporting Earnings Today (July 22)

Kapitall submits:Here is a list of 15 companies releasing earning statements on July 22. We've sorted the companies by market cap, and have briefly discussed their earnings performance over the past 3 years. The charts show past earning performances against analyst estimates. The green markers indicate the company beating estimates, while the red makers represent the company falling short of analyst expectations. All data is sourced from Zacks Investment Research.Complete Story »

15 Companies Reporting Earnings Today (July 22)

Kapitall submits:Here is a list of 15 companies releasing earning statements on July 22. We've sorted the companies by market cap, and have briefly discussed their earnings performance over the past 3 years. The charts show past earning performances against analyst estimates. The green markers indicate the company beating estimates, while the red makers represent the company falling short of analyst expectations. All data is sourced from Zacks Investment Research.Complete Story »

Sanofi-Aventis on the Prowl

The Burrill Report submits: by Marie DaghlianEver since CEO Chris Veihbacher took the helm of France’s largest pharmaceutical company in September 2008, he has actively looked outside Sanofi-Aventis (SNY) for ways to stem the impending loss of over one third of its revenue from patent expirations. A Burrill Report analysis shows that he has spent $17 billion to expand and diversify the company, including more than $9 billion in acquisitions ranging from small biotechs to companies focused on generic drugs, animal health, and emerging markets. Now, reports say he’s ready to eclipse that in a single deal. Complete Story »

The 14 Highest Yielding Dividend Champions

David Van Knapp submits:The U. S. Dividend Champions List—produced by the DRiP Investing Resource Center—is the best compilation I know of domestic stocks that have raised their dividends for the past 25 years. I think it is superior to the more famous Dividend Aristocrats List from S&P. Its methodology seems more thorough, it is not restricted to stocks on the S&P 500 index, and its rules are well explained and observed religiously. It is a model of a well-documented, fact-based research tool. The Dividend Champions list is produced by David Fish, who I am happy to see contributes occasional articles and comments to Seeking Alpha. His insights benefit all dividend investors. There is a lot of talk among dividend investors about the merits of high-yielding stocks vs. lower-yielding stocks. It is often said that the high yielders, while giving you a better initial payout, often represent risky propositions: Their high yield is the result of an excessive payout ratio, or a highly cyclical business, or a company whose stock price has tanked because the company itself is in trouble. It is said that they may have high yields, but the yields increase by miniscule amounts, if at all. The thinking goes, these are stocks with dividend cuts just around the corner and stock price collapses in the offing. Fans of high yielders, on the other hand, argue that they want the best return on their money now. They cannot or do not want to wait for lower-yielding stocks to get up to higher yields on cost, even if the lower yielders have extraordinarily high rates of dividend increases that will eventually propel them past the current high yielders. I write an annual e-book on dividend-growth investing (current edition: The Top 40 Dividend Stocks for 2010: How to Generate Wealth or Income from Dividend Stocks), and I wrestle with these issues every year. There are always high-yield stocks on my radar screen, but to have a credible book with a year’s shelf-life, I cannot load it up with risky high yielders that may cut their dividends during the year. I use a variety of analytical tools to weed out the stocks whose dividends are most in peril. But the frequent appearance of this subject on Seeking Alpha got me thinking about it “inside out”: Are there any high-yielding stocks that have raised their dividends for 25 years straight? One must first decide what is a “high” yield. We can all agree that 0.3% is a low dividend and 18% is a high one. But where do you draw the line? Recently, Dividends4Life wrote an article on dividend risk. He used a simple categorization system in which he considered dividends of 8% or more to be at the highest risk. (He also used other factors to come up with an overall risk score.) Let’s steal his definition: A stock is a “high” dividend stock if its current yield is 8% or more. Are there any stocks out there with both a 25-year dividend increase streak and a current yield of 8% or more? Yes. Just one: CenturyLink (CTL) has a current yield of 8.7%. It is the only stock on the Dividend Champions list with a yield of 7% or higher (Altria has a 6.99% dividend, which rounds to 7%). Here are the 14 stocks on the Dividend Champions list with yields over 5%, in descending order of current yield:

  • CenturyLink (CTL) 8.7%, 37 year streak of annual increases
  • Altria (MO) 7.0%, 42
  • AT&T (T) 7.0%, 26 years
  • Pitney Bowes (PBI) 6.7%, 28 years
  • Washington REIT (WRE) 6.3%, 38 years
  • Integrys Energy Group (TEG) 6.2%, 51 years
  • Cincinnati Financial (CINF) 6.1%, 49 years
  • Eli Lilly (LLY) 5.9%, 42 years
  • Vectren (VVC) 5.8%, 50 years
  • Old Republic International (ORI) 5.7%, 29 years
  • Consolidated Edison (ED) 5.5%, 36 years
  • Leggett & Platt (LEG) 5.2%, 39 years
  • Black Hills (BKH) 5.1%, 40 years
  • United Bancshares (UBSI) 5.0%, 36 years

It should be noted that I do not mean to suggest that these are all great stocks for dividend investors. Some of them have badly underperformed the market over the past several years, others have shaky balance sheets. Three have gone more than one year without raising their dividend (Integrys, Eli Lilly, Washington REIT). Their consecutive-year streaks may be ending this year. One other point, regarding high yielders typically having lower rates of dividend increases. Among these 14 stocks, the average of their last increases was just 2.3%. Only one—Eli Lilly—exceeded 4%, and as we have seen, Lilly’s streak may be over. By comparison, the average most-recent increase for the 100 companies on the Dividend Champions list was 5.4%. So from this small sample, there does appear to be truth to the criticism that high yielding stocks tend to increase their dividends more slowly than lower-yielding stocks, and that over time, the “better” investments may be lower yielders with higher rates of dividend increases. (For an article explaining the dynamics over time of current yield with rate of increase, see “10 by 10: A New Way to Look at Dividend Yield and Growth.”)Disclosure: Long CTL, TComplete Story »

Eli Lilly: This Big Pharma Needs to Get Better

Steve Alexander submits:Eli Lilly (LLY) is one of the largest of the "big pharmaceutical" companies, focusing especially on the clinical areas of the nervous system, endocrine system (hormones), cancer, and the cardiovascular system (heart and lungs). The firm also has a substantial veterinary drug business.Lilly's largest and most important drug is Zyprexa, which is used to treat schizophrenia and bipolar disorders. In 2009, Zyprexa totaled $4.9 billion dollars in sales, putting it easily within the top 10 selling drugs worldwide and representing about 22% of Eli Lilly's total revenues. Cymbalta, a strong antidepressant, delivered $3.1 billion in sales, an impressive 15% increase over 2008 and 14% of the firm's total sales. Other blockbuster contributors include: Humalog, an insulin substitute ($1.96 billion); Alimta, a lung cancer treatment ($1.7 billion); Cialis, for erectile dysfunction ($1.56 billion); Gemzar, a pancreatic cancer drug ($1.36 billion); and Evista, for osteoporosis ($1.03 billion). In all, the company has a pretty impressive portfolio of drugs, with less concentration risk than many competitors.Complete Story »

6 Dividend Aristocrat Stocks to Consider

Scott's Investments submits: In a continued effort to expand the focus of my site's screens and hypothetical portfolios, this article is a second follow-up to an article written in early April focusing on the S&P 500 Dividend Aristocrats. The S&P 500 Dividend Aristocrats index measures the performance of large cap, blue chip companies within the S&P 500 that have followed a policy of increasing dividends every year for at least 25 consecutive years. The current list has 43 constituents and the entire list is available from S&P or on my site. If an investor's portfolio was large enough he or she could consider purchasing the entire list.Alternatively, an investor could invest in the [[SDY]], the SPDR Dividend ETF, which is a variation of the Aristocrats - it seeks to replicate the “High Yield” Dividend Aristocrats Index. A third alternative is to start with the Aristocrat list and then reduce the list of candidates through screens and/or fundamental analysis. I screened for Aristocrats which had a sustainable payout ratio, a high dividend yield, relatively low debt/equity ratio, and positive return on assets and equity. Using Finviz, which has some of the better screeners and charts available, I screened the Aristocrat list for:

    • Payout Ratio < 80%,
    • Dividend Yield > 3%
    • Return on Assets > 10%
    • Return on Equity > 10%
    • Total Debt/Equity < 1

Below is a list of 6 Aristocrats which are worthy of further consideration, especially if one is seeking yield or seeking to reduce exposure to non-dividend paying companies. All of the companies on the list are familiar names and they were also all on last month's list with the exception of [[JNJ]]. Ticker Company Free Trend Analysis Dividend Yield Payout Ratio Performance (Half Year) Price [[LLY]] Eli Lilly & Co. Here 5.65% 52.87% 0.55% 34.66 [[JNJ]] Johnson & Johnson Here 3.65% 40.66% -6.74% 59.13 [[ABT]] Abbott Laboratories Here 3.64% 47.77% -8.44% 48.3 [[KO]] The Coca-Cola Company Here 3.35% 54.40% -6.35% 52.48 [[MCD]] McDonald's Corp. Here 3.15% 48.79% 14.83% 69.92 [[MHP]] The McGraw-Hill Companies, Inc.Disclosure: No positionsComplete Story »

Lilly Beats, But Healthcare Reform Will Hurt Going Forward

Zacks.com submits:
Eli Lilly (LLY) reported first quarter earnings per share of $1.18, a couple of cents below the year-ago earnings of $1.20, but above the Zacks Consensus Estimate of $1.11. Results included a 12-cent impact due to the US health care reform. Excluding this impact, earnings would have increased 4% from the year ago period. Revenues recorded a 9% year-over-year increase to $5.49 billion, driven by an increase in volume (4%), prices (1%) as well as a favorable impact of foreign exchange (3%).Complete Story »

Top 10 Dividend Paying Stocks On Our Watch List

Dividend Inc. submits:
At the end of the week, our top ten stocks on our watch list contains a very diverse group of companies. These dividend paying stocks are all within 20% of the 52-week low for April 16, 2010.SymbolNamePrice% Yr LowP/EEPSDiv/ShrYieldPayout RatioMONMonsanto Co.64.73-0.69%26.972.401.061.64%44%XOMExxon Mobil Corp.67.936.88%17.083.981.682.47%42%FPLFPL Group, Inc.48.436.93%12.213.972.004.13%50%TMPTompkins Financial Corp.37.748.93%12.752.961.363.60%46%DNBDun & Bradstreet Corp.76.3110.43%12.726.001.401.83%23%TAT&T Inc.25.9311.82%12.242.121.686.48%79%FRSFrisch's Restaurants, Inc.22.3512.26%9.932.250.522.33%23%FFINFirst Financial Bankshares52.6113.24%20.392.581.362.59%53%BROBrown & Brown, Inc.18.5913.91%17.231.080.311.67%29%LLYEli Lilly and Co.36.5414.08%9.273.941.965.36%50%Watch List SummaryThe best performing stock from last week's list was Shenandoah Telecom (SHEN) which rose 4.8%. The worst performing stock, once again, was Monsanto which fell another 6% (it fell 2.8% last week). Overall, the Dividend Achiever watch list gained 0.2% versus the Dow which was flat.Complete Story »

Lilly 'Aggressively' Investing in China

ChinaBio Today submits: Eli Lilly (NYSE: LLY) is investing “aggressively” in China, according to the company’s CEO John Lechleiter. To give substance to the claim, Lechleiter said Lilly will launch 15 new products in China over the next five years, has already made $40 million in venture capital investments from its $100 million China VC fund, and, not surprisingly, expects to increase its China revenues this year. Lechleiter made his comments, which were reported by Reuters, at a Shanghai pharmaceutical conference, being held this week. Complete Story »

Eisai Revenues Set to Fall Off the 'Patent Cliff' as Sepsis Drug Hits Delay

EP Vantage submits:Bigger is definitely not better for Eisai’s share priceWith patent expiry of its lead drug galloping towards it at high speed, the last thing that Eisai (ESALY.PK) needed was a delay to one of the drugs it had picked as a cornerstone product to help it get over generic competition to Alzheimer’s treatment, Aricept, in November.Complete Story »

Syndicate content